Get better Answers
With Innovative, Adaptive Clinical Trials.
Berry Consultants ("Berry") is a scientific consulting company specializing in innovative adaptive clinical trial design, analysis, implementation, and software solutions for the pharmaceutical and medical device industry.
To seek efficient answers for new medical advancements, you need more. That’s why Berry offers innovative statisticians and software for the freedom to design and implement adaptive clinical trials. Get the answers you need from analysis to approval and beyond.
Innovative Trials, Better Outcomes.
Berry has extensive experience in the design, implementation, and software solutions of adaptive clinical trials across many medical disciplines. Adaptive trials can result in better insights, greater efficiency, better treatment for subject in a trial, and better information for regulators and the medical community. Here’s the Adaptive Trial Process.
Adaptive Clinical Trial Design
Allow the pre-specification of flexible components to the major aspects of a trial, like the treatment arms, the allocation to the different treatment arms, the patient population, and the sample size.
Trial Implementation
Our services include interim and final analyses for primary and key secondary efficacy endpoints, providing expert guidance on best practices for adaptive design implementation, and interacting with Data Safety Monitoring Boards (DSMB) for adaptive and platform trials.
Clinical Trial Software
Software solutions that help Biostatisticians rapidly design, compare, and simulate both fixed and adaptive trial designs through powerful, versatile and fast simulation tools.
Platform Trials
Innovative clinical trials that evaluate multiple treatments simultaneously and intended to continue beyond the evaluation of any one treatment, while maximizing statistical and clinical efficiency.
Latest News and Events
Episode 47, “A Visit with Michael Harhay”
In this episode of "In the Interim…", Dr. Scott Berry speaks with Dr. Michael Harhay, Associate Professor at the University of Pennsylvania and Director of the Center for Clinical Trials Innovation.
Blog released on “Guide to the Draft FDA Bayesian Guidance 2026”
The FDA Draft Bayesian guidance is a dramatic leap forward for Bayesian clinical trials and regulatory science. In this blog, Dr. Kert Viele outlines the key concepts and motivations for the guidance recommendations.
Episode 46, “The FDA Bayesian Guidance”
In this episode of "In the Interim…", Dr. Scott Berry and Dr. Kert Viele deliver a quick reaction to the FDA’s draft guidance on Bayesian statistics for clinical trials of drugs and biologics.
Episode 45, “Path 2 Parkinson’s Prevention with Drs. Simuni and Wendelberger”
In this episode of "In the Interim…", Dr. Scott Berry is joined by Dr. Tanya Simuni, Arthur C. Nielsen Jr. Professor of Neurology and Director of the Parkinson’s Disease and Movement Disorders Center at Northwestern University, and Dr. Barbara Wendelberger, Senior Statistical Scientist at Berry Consultants.
Latest Publications
We’re continually refining and reshaping the clinical trials for the betterment of our clients and their patients.
